Combining 18F‐FDG PET/CT and Serum Lactate Dehydrogenase for Prognostic Evaluation of Small Cell Lung Cancer

Xiaoping Lin,Zizheng Xiao,Yingying Hu,Xu Zhang,Wei Fan

DOI: https://doi.org/10.3389/fphar.2020.592768

IF: 5.6

2020-10-28

Frontiers in Pharmacology

Abstract:<span><strong>Objective:</strong> To investigate the value of using ¹⁸F-FDG PET/CT in combination with serum lactate dehydrogenase (LDH) for prognostic evaluation of newly diagnosed small cell lung cancer (SCLC).<strong>Methods:</strong> We reviewed 118 patients with pathologically proven SCLC who underwent ¹⁸F-FDG PET/CT imaging evaluation in our hospital. Among these patients, 64 patients had extensive disease (ED) and 54 patients had limited disease (LD). The maximum standardized uptake value (SUV_max) of primary tumor was measured. A Cox proportional hazards model was used to evaluate age, sex, performance status, serum LDH, tumor stage and SUV_max on the prediction of overall survival (OS) and median survival time (MST) of patients. Subgroup analysis was performed based on the SUV_max in combination with serum LDH.<strong>Results:</strong> According to the Receiver Operating Characteristic (ROC) curve, the optimal cut-off value of SUV_max was 10.95. The AUC was 0.535 (95% CI: 0.407–0.663). The patients were divided into four groups according to the SUV_max (higher or lower than 10.95) and LDH (higher or lower than 245 U/L). The univariate and multivariate analyses showed that curative thoracic radiotherapy, Prophylactic Cranial Irradiation (PCI) and the combination of primary tumor SUV_max ≤ 10.95 and LDH ≤ 245 U/L were prognostic factors of OS in patients with all patients (<em>p &lt;</em> 0.05). Smoking status, PCI, the combination of primary tumor SUV_max ≤ 10.95 and LDH ≤ 245 U/L were prognostic factors of OS in patients with LD (<em>p &lt;</em> 0.05). N stage and PCI were significant predictors in both of univariate and multivariate analysis of OS for ED SCLC (<em>p &lt;</em> 0.05). Among all patients, 27 had low SUV_max and normal LDH, and their MST was 36 months (95% CI: 12.98–59.02). Ninety-one patients had high SUV_max and/or high LDH, and their MST was 20 months (95% CI: 15.47–24.53). The difference between these two groups was significant (<em>p</em> = 0.045). In patients with LD, 16 patients had low SUV_max and normal LDH, and their MST was 72 months (95% CI: 26.00–118.0). Thirty-eight patients had high SUV_max and/or high LDH, and their MST was 27 months (95% CI: 20.80–33.21). The difference between these two groups was significant (<em>p</em> = 0.012). In patients with ED SCLC, 10 patients had low SUV_max and normal LDH, with an MST of 18 months (95% CI: 13.69–22.32. Fifty-four patients had high SUV_max and/or high LDH, and their MST was 12 months (95% CI: 10.61–13.39). The difference of MST between these two groups was not statistically significant (<em>p</em> = 0.686).<strong>Conclusion:</strong>¹⁸F-FDG PET/CT in combination with serum LDH were prognostic factors of overall survival in patients with SCLC. The prognosis of patients with LD SCLC who had low SUV_max of primary tumor and normal LDH was better than those with high SUV_max and/or high LDH.</span>

pharmacology & pharmacy